



Author index

Volume 45 (1997)

- Allan Klock, P. 45, 63
Apfelbaum, J.L. 45, 63
- Babor, T.F. 45, 13, 93
Ball, C.E. 45, 105
Beratis, S. 45, 207
Berlin, I. 45, 31
Bigelow, G.E. 45, 81
Brooner, R.K. 45, 105
Budney, A.J. 45, 1
Burleson, J.A. 45, 157
- Carroll, M.E. 45, 21
Cherek, D.R. 45, 1
Cho, A.M. 45, 63
Coalson, D.W. 45, 63
Coiro, V. 45, 115
Creson, D.R. 45, 143
- Danjou, P. 45, 177
Dawes, M.A. 45, 165
Del Boca, F.K. 45, 13
Dewey, W.L. 45, 47
Dykstra, L.A. 45, 197
- E. Fantegrossi, W. 45, 71
Eissenberg, T. 45, 81
- Fendrich, M. 45, 185
Frosch, D. 45, 131
- Gazaway, P.M. 45, 105
Glowa, J.R. 45, 71
Golden, A.S. 45, 105
Goldstein, P.J. 45, 185
- Huggins, G.R. 45, 105
Hughes, C.E. 45, 197
- Johnson, R.E. 45, 81
- Kadden, R.M. 45, 93
Kandel, D.B. 45, 1
Kirisci, L. 45, 165
Klafta, J.M. 45, 63
Kokkevi, A. 45, 55
Kranzler, H.R. 45, 93, 157
- Launay, J.-M. 45, 31
Lekka, N.P. 45, 207
Leventakou, V. 45, 55
Liebson, I.A. 45, 81
Ling, W. 45, 131
- Mackesy-Amiti, M.E. 45, 185
Marks, S. 45, 63
Martin, B.R. 45, 1
Mattox, A.J. 45, 21
McCann, M.J. 45, 131
McCaul, M.E. 45, 105
McRee, B. 45, 13
Meisch, R.A. 45, 143
Miller, P. 45, 121
Miotto, K. 45, 131
- Palermou, B. 45, 55
Paschalidis, C. 45, 207
Payan, C. 45, 177
Pickens, R.W. 45, 105
Puech, A.-J. 45, 177
- Rawson, R.A. 45, 131
Richardson, C. 45, 55
Roache, J.D. 45, 143
Rodefer, J.S. 45, 21
Roffman, R. 45, 1
Rosendale, C.T. 45, 105
Rounsville, B.J. 45, 93
- Said, S. 45, 31
Shah, N.N. 45, 143
Skipsey, K. 45, 157
Smith, F.L. 45, 47
Spreux-Varoquaux, O. 45, 31
Stanley, M.A. 45, 143
Stephens, R.S. 45, 1
S. Thompson, S. 45, 21
Stitzer, M.L. 45, 81, 105
Strain, E.C. 45, 81
Svikis, D.S. 45, 105
- Tarter, R.E. 45, 165
Tennen, H. 45, 93
Toledano, A.Y. 45, 63
- Velez, M.L. 45, 105
Vescovi, P.P. 45, 115
- Walsh, S.L. 45, 81
Warot, D. 45, 177
Welch, S.P. 45, 39, 47
- Zacny, J.P. 45, 63





Subject index

Volume 45 (1997)

Addiction Research Center Inventory (ARCI); Healthy subjects; Amphetamine; Reliability; Sensitivity; Specificity; ROC analysis **45**, 177

Adolescents; Family structure; Illicit drugs; Smoking; Alcohol; Personality **45**, 121

Agonists; Cocaine; Self-administration; Replacement/substitution therapy; Drug reinforcement; Rhesus monkeys **45**, 71

Alcohol; Benzodiazepine; Caffeine; Cigarette smoking; Substance dependence **45**, 207

Alcohol; Family structure; Adolescents; Illicit drugs; Smoking; Personality **45**, 121

Alcoholism; Amenorrhea; Prolactin; Metoclopramide; TRH **45**, 115

Alcohol; Nitrous oxide; Reinforcing; Choice; Subjective; Mood; Psychomotor; Behavior; History; Human **45**, 63

Alcohol; Secondary analysis; Marijuana; Gateway drug; Prevention efforts **45**, 185

Alprazolam; Benzodiazepines; Anxiety; Panic; Reinforcement; Self-administration; Self-medication **45**, 143

Alternative reinforcer; Behavioral economics; Buprenorphine; Cocaine; Inhalation; Rhesus monkeys; Saccharin; Self-administration; Smoking **45**, 21

Amenorrhea; Alcoholism; Prolactin; Metoclopramide; TRH **45**, 115

Amphetamine; Addiction Research Center Inventory (ARCI); Healthy subjects; Reliability; Sensitivity; Specificity; ROC analysis **45**, 177

Anandamide; Δ^9 -THC; CP55,940; Dynorphins; Tolerance **45**, 39

Antagonist-precipitated withdrawal; Buprenorphine; Less-than-daily-dosing; Opioid antagonists; Physical dependence; Spontaneous withdrawal **45**, 81

Anxiety; Benzodiazepines; Alprazolam; Panic; Reinforcement; Self-administration; Self-medication **45**, 143

ATP-gated potassium channels; Morphine; Tolerance; Glyburide binding; CNS **45**, 47

AUDIT; Drug-dependent patients; Harmful drinking **45**, 157

Behavioral economics; Alternative reinforcer; Buprenorphine; Cocaine; Inhalation; Rhesus monkeys; Saccharin; Self-administration; Smoking **45**, 21

Behavioral self-regulation; Drug abuse; Etiology; Liability; Child development **45**, 165

Behavior; Nitrous oxide; Reinforcing; Choice; Subjective; Mood; Psychomotor; Alcohol; History; Human **45**, 63

Benzodiazepine; Alcohol; Caffeine; Cigarette smoking; Substance dependence **45**, 207

Benzodiazepines; Alprazolam; Anxiety; Panic; Reinforcement; Self-administration; Self-medication **45**, 143

Buprenorphine; Alternative reinforcer; Behavioral economics; Cocaine; Inhalation; Rhesus monkeys; Saccharin; Self-administration; Smoking **45**, 21

Buprenorphine; Less-than-daily-dosing; Opioid antagonists; Antagonist-precipitated withdrawal; Physical dependence; Spontaneous withdrawal **45**, 81

Caffeine; Alcohol; Benzodiazepine; Cigarette smoking; Substance dependence **45**, 207

Cannabinoid; Marijuana use; Dependence **45**, 1

Child development; Drug abuse; Etiology; Behavioral self-regulation; Liability **45**, 165

Choice; Nitrous oxide; Reinforcing; Subjective; Mood; Psychomotor; Alcohol; Behavior; History; Human **45**, 63

Cigarette smoking; Alcohol; Benzodiazepine; Caffeine; Substance dependence **45**, 207

CNS; Morphine; ATP-gated potassium channels; Tolerance; Glyburide binding **45**, 47

Cocaine; Alternative reinforcer; Behavioral economics; Buprenorphine; Inhalation; Rhesus monkeys; Saccharin; Self-administration; Smoking **45**, 21

Cocaine; Self-administration; Replacement/substitution therapy; Drug reinforcement; Agonists; Rhesus monkeys **45**, 71

Cost-Effectiveness; Pregnancy; Drug dependence; Treatment; Outcome **45**, 105

- CP55,940;** Anandamide; Δ^9 -THC; Dynorphins; Tolerance **45**, 39
- Dependence;** Marijuana use; Cannabinoid **45**, 1
- Dependent smokers;** Past history of depression; Monoamine oxidases; Withdrawal symptoms **45**, 31
- Diagnosis;** Reliability; SCID; DSM-III-R **45**, 13
- Diagnostic validity;** LEAD procedure; Substance abuse **45**, 93
- Drug abuse;** Etiology; Behavioral self-regulation; Liability; Child development **45**, 165
- Drug dependence;** Pregnancy; Treatment; Cost-Effectiveness; Outcome **45**, 105
- Drug dependence;** Self reports; Reliability **45**, 55
- Drug-dependent patients;** AUDIT; Harmful drinking **45**, 157
- Drug reinforcement;** Cocaine; Self-administration; Replacement/substitution therapy; Agonists; Rhesus monkeys **45**, 71
- DSM-III-R;** Reliability; Diagnosis; SCID **45**, 13
- Dynorphins;** Anandamide; Δ^9 -THC; CP55,940; Tolerance **45**, 39
- Etiology;** Drug abuse; Behavioral self-regulation; Liability; Child development **45**, 165
- Family structure;** Adolescents; Illicit drugs; Smoking; Alcohol; Personality **45**, 121
- Fixed-ratio schedule;** Meperidine; Morphine; β -Funaltrexamine; Naltrexone; Response-rate; Squirrel monkey **45**, 197
- β -Funaltrexamine;** Meperidine; Morphine; Naltrexone; Response-rate; Fixed-ratio schedule; Squirrel monkey **45**, 197
- Gateway drug;** Secondary analysis; Marijuana; Alcohol; Prevention efforts **45**, 185
- Glyburide binding;** Morphine; ATP-gated potassium channels; Tolerance; CNS **45**, 47
- Harmful drinking;** AUDIT; Drug-dependent patients **45**, 157
- Healthy subjects;** Addiction Research Center Inventory (ARCI); Amphetamine; Reliability; Sensitivity; Specificity; ROC analysis **45**, 177
- Heroin;** Naltrexone; Treatment; Overdose; Mortality; Opioids **45**, 131
- History;** Nitrous oxide; Reinforcing; Choice; Subjective; Mood; Psychomotor; Alcohol; Behavior; Human **45**, 63
- Human;** Nitrous oxide; Reinforcing; Choice; Subjective; Mood; Psychomotor; Alcohol; Behavior; History **45**, 63
- Illicit drugs;** Family structure; Adolescents; Smoking; Alcohol; Personality **45**, 121
- Inhalation;** Alternative reinforcer; Behavioral economics; Buprenorphine; Cocaine; Rhesus monkeys; Saccharin; Self-administration; Smoking **45**, 21
- LEAD procedure;** Diagnostic validity; Substance abuse **45**, 93
- Less-than-daily-dosing;** Buprenorphine; Opioid antagonists; Antagonist-precipitated withdrawal; Physical dependence; Spontaneous withdrawal **45**, 81
- Liability;** Drug abuse; Etiology; Behavioral self-regulation; Child development **45**, 165
- Marijuana;** Secondary analysis; Alcohol; Gateway drug; Prevention efforts **45**, 185
- Marijuana use;** Cannabinoid; Dependence **45**, 1
- Meperidine;** Morphine; β -Funaltrexamine; Naltrexone; Response-rate; Fixed-ratio schedule; Squirrel monkey **45**, 197
- Metoclopramide;** Alcoholism; Amenorrhea; Prolactin; TRH **45**, 115
- Monoamine oxidases;** Dependent smokers; Past history of depression; Withdrawal symptoms **45**, 31
- Mood;** Nitrous oxide; Reinforcing; Choice; Subjective; Psychomotor; Alcohol; Behavior; History; Human **45**, 63
- Morphine;** ATP-gated potassium channels; Tolerance; Glyburide binding; CNS **45**, 47
- Morphine;** Meperidine; β -Funaltrexamine; Naltrexone; Response-rate; Fixed-ratio schedule; Squirrel monkey **45**, 197
- Mortality;** Naltrexone; Heroin; Treatment; Overdose; Opioids **45**, 131
- Naltrexone;** Heroin; Treatment; Overdose; Mortality; Opioids **45**, 131
- Naltrexone;** Meperidine; Morphine; β -Funaltrexamine; Response-rate; Fixed-ratio schedule; Squirrel monkey **45**, 197
- Nitrous oxide;** Reinforcing; Choice; Subjective; Mood; Psychomotor; Alcohol; Behavior; History; Human **45**, 63
- Opioid antagonists;** Buprenorphine; Less-than-daily-dosing; Antagonist-precipitated withdrawal; Physical dependence; Spontaneous withdrawal **45**, 81
- Opioids;** Naltrexone; Heroin; Treatment; Overdose; Mortality **45**, 131
- Outcome;** Pregnancy; Drug dependence; Treatment; Cost-Effectiveness **45**, 105
- Overdose;** Naltrexone; Heroin; Treatment; Mortality; Opioids **45**, 131
- Panic;** Benzodiazepines; Alprazolam; Anxiety; Reinforcement; Self-administration; Self-medication **45**, 143
- Past history of depression;** Dependent smokers; Monoamine oxidases; Withdrawal symptoms **45**, 31
- Personality;** Family structure; Adolescents; Illicit drugs; Smoking; Alcohol **45**, 121

- Physical dependence;** Buprenorphine; Less-than-daily-dosing; Opioid antagonists; Antagonist-precipitated withdrawal; Spontaneous withdrawal **45**, 81
- Pregnancy;** Drug dependence; Treatment; Cost-Effectiveness; Outcome **45**, 105
- Prevention efforts;** Secondary analysis; Marijuana; Alcohol; Gateway drug **45**, 185
- Prolactin;** Alcoholism; Amenorrhea; Metoclopramide; TRH **45**, 115
- Psychomotor;** Nitrous oxide; Reinforcing; Choice; Subjective; Mood; Alcohol; Behavior; History; Human **45**, 63
- Reinforcement;** Benzodiazepines; Alprazolam; Anxiety; Panic; Self-administration; Self-medication **45**, 143
- Reinforcing;** Nitrous oxide; Choice; Subjective; Mood; Psychomotor; Alcohol; Behavior; History; Human **45**, 63
- Reliability;** Addiction Research Center Inventory (ARCI); Healthy subjects; Amphetamine; Sensitivity; Specificity; ROC analysis **45**, 177
- Reliability;** Diagnosis; SCID; DSM-III-R **45**, 13
- Reliability;** Drug dependence; Self reports **45**, 55
- Replacement/substitution therapy;** Cocaine; Self-administration; Drug reinforcement; Agonists; Rhesus monkeys **45**, 71
- Response-rate;** Meperidine; Morphine; β -Funaltrexamine; Naltrexone; Fixed-ratio schedule; Squirrel monkey **45**, 197
- Rhesus monkeys;** Alternative reinforcer; Behavioral economics; Buprenorphine; Cocaine; Inhalation; Saccharin; Self-administration; Smoking **45**, 21
- Rhesus monkeys;** Cocaine; Self-administration; Replacement/substitution therapy; Drug reinforcement; Agonists **45**, 71
- ROC analysis;** Addiction Research Center Inventory (ARCI); Healthy subjects; Amphetamine; Reliability; Sensitivity; Specificity **45**, 177
- Saccharin;** Alternative reinforcer; Behavioral economics; Buprenorphine; Cocaine; Inhalation; Rhesus monkeys; Self-administration; Smoking **45**, 21
- SCID;** Reliability; Diagnosis; DSM-III-R **45**, 13
- Secondary analysis;** Marijuana; Alcohol; Gateway drug; Prevention efforts **45**, 185
- Self-administration;** Alternative reinforcer; Behavioral economics; Buprenorphine; Cocaine; Inhalation; Rhesus monkeys; Saccharin; Smoking **45**, 21
- Self-administration;** Benzodiazepines; Alprazolam; Anxiety; Panic; Reinforcement; Self-medication **45**, 143
- Self-administration;** Cocaine; Replacement/substitution therapy; Drug reinforcement; Agonists; Rhesus monkeys **45**, 71
- Self-medication;** Benzodiazepines; Alprazolam; Anxiety; Panic; Reinforcement; Self-administration **45**, 143
- Self reports;** Drug dependence; Reliability **45**, 55
- Sensitivity;** Addiction Research Center Inventory (ARCI); Healthy subjects; Amphetamine; Reliability; Specificity; ROC analysis **45**, 177
- Smoking;** Alternative reinforcer; Behavioral economics; Buprenorphine; Cocaine; Inhalation; Rhesus monkeys; Saccharin; Self-administration **45**, 21
- Smoking;** Family structure; Adolescents; Illicit drugs; Alcohol; Personality **45**, 121
- Specificity;** Addiction Research Center Inventory (ARCI); Healthy subjects; Amphetamine; Reliability; Sensitivity; ROC analysis **45**, 177
- Spontaneous withdrawal;** Buprenorphine; Less-than-daily-dosing; Opioid antagonists; Antagonist-precipitated withdrawal; Physical dependence **45**, 81
- Squirrel monkey;** Meperidine; Morphine; β -Funaltrexamine; Naltrexone; Response-rate; Fixed-ratio schedule **45**, 197
- Subjective;** Nitrous oxide; Reinforcing; Choice; Mood; Psychomotor; Alcohol; Behavior; History; Human **45**, 63
- Substance abuse;** LEAD procedure; Diagnostic validity **45**, 93
- Substance dependence;** Alcohol; Benzodiazepine; Caffeine; Cigarette smoking **45**, 207
- Δ^9 -THC;** Anandamide; CP55,940; Dynorphins; Tolerance **45**, 39
- Tolerance;** Anandamide; Δ^9 -THC; CP55,940; Dynorphins **45**, 39
- Tolerance;** Morphine; ATP-gated potassium channels; Glyburide binding; CNS **45**, 47
- Treatment;** Naltrexone; Heroin; Overdose; Mortality; Opioids **45**, 131
- Treatment;** Pregnancy; Drug dependence; Cost-Effectiveness; Outcome **45**, 105
- TRH;** Alcoholism; Amenorrhea; Prolactin; Metoclopramide **45**, 115
- Withdrawal symptoms;** Dependent smokers; Past history of depression; Monoamine oxidases **45**, 31



